Jun. 25 at 6:31 PM
$BCTX Post-translational modifications (PTMs):
Cancer cells can express dozens and dozens of traditional, cancer-associated antigens. Most of these are fairly well known, and many have been targeted by specific therapies because they are common among many patients. However, cancer's ability to mutate and evade these therapies still persists.
On the other end of the spectrum are the neoantigens, which are truly specific to an individual, and their own, mutated cancer cells. Some therapies are designed to simply kill enough cancer cells, that these released neoantigens might stimulate an additional immune response against the cancer.
PTMs are kinda "in-between". These are the tell-tale signs of cellular mutations. Not the previous antigens, not the neoantigens, but signals that the cancer cells have mutated. These can be common among many patients, unlike the neoantigens, and represent a very promising avenue for immunotherapy.
BriaCell's patented cell line expresses many of these PTMs.
